Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 9, 981 (2003)
doi:10.1038/nm0803-981a
'Emancipated' biotechs offer new drugs for neurodegeneration
Paroma Basu1
- New York
Six new drugs for the rare neurodegenerative disease amyotrophic lateral sclerosis (ALS) are poised to enter clinical trials this fall. Of those, two—ritonavir and hydroxyurea—are products of a tiny, young nonprofit biotechnology company.
To read this story in full you will need to login or make a payment (see right).
